These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22413956)

  • 1. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema.
    Simon TL; Kalina U; Laske R; Mycroft S; Widmer E; Roth NJ
    Allergy Asthma Proc; 2020 Mar; 41(2):99-107. PubMed ID: 31796151
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
    Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
    Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
    Cai K; Gröner A; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gajardo R; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Lee DC; Moscardini M; Pölsler G; Roth NJ
    Transfusion; 2013 Sep; 53(9):1894-905. PubMed ID: 23252676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human C1-esterase inhibitor concentrate (Berinert).
    Keating GM
    BioDrugs; 2009; 23(6):399-406. PubMed ID: 19894781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process.
    Barnette D; Roth NJ; Hotta J; Cai K; Gall M; Hartwell R; Kent JD; Willis T
    Biologicals; 2012 Jul; 40(4):247-53. PubMed ID: 22579294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety.
    Hofstra JJ; Kleine Budde I; van Twuyver E; Choi G; Levi M; Leebeek FW; de Monchy JG; Ypma PF; Keizer RJ; Huitema AD; Strengers PF
    Clin Immunol; 2012 Mar; 142(3):280-90. PubMed ID: 22197071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.
    Bernstein JA; Ritchie B; Levy RJ; Wasserman RL; Bewtra AK; Hurewitz DS; Obtulowicz K; Reshef A; Moldovan D; Shirov T; Grivcheva-Panovska V; Kiessling PC; Schindel F; Craig TJ
    Ann Allergy Asthma Immunol; 2010 Aug; 105(2):149-54. PubMed ID: 20674826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.